MMEA
LGND icon

Main Management ETF Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Main Management ETF Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-7,330
Closed -$833K – 161
2025
Q2 		$833K Buy
7,330
+120
+2% +$12.8K 0.03% 101
2025
Q1 		$758K Buy
+7,210
New +$815K 0.04% 94

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Main Management ETF Advisors's LGND Position: Q3 2025 in Review

Main Management ETF Advisors sold out of Ligand Pharmaceuticals (LGND) in Q3 2025, closing a stake of 7,330 shares — an estimated $833K sold.

Main Management ETF Advisors first reported a position in LGND in Q1 2025 and held it in 2 quarters. The position peaked at $833K in Q2 2025. 314 funds tracked by Wall St. Rank hold LGND as of Q3 2025.

  • Main Management ETF Advisors reported no remaining Ligand Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Main Management ETF Advisors sold 7,330 Ligand Pharmaceuticals shares in Q3 2025, an estimated $833K.
  • Main Management ETF Advisors first reported a position in Ligand Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Main Management ETF Advisors's Ligand Pharmaceuticals position peaked at $833K in Q2 2025.
  • 314 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2025.

Based on Main Management ETF Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.